Innovations in Biomaterial Technology: Our advancements in biomaterial technology have been nothing short of groundbreaking. The results from our studies presented at the AVA Annual Scientific Meeting have shown our MIMIX hydrophilic biomaterial (HBM) to significantly reduce bacterial adhesion and thrombus accumulation. This innovation could revolutionize the way we approach vascular access, with potential to significantly lower the risks associated with central-line associated bloodstream infections (CLABSI).
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules